ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologic response modifiers and pediatric rheumatology"

  • Abstract Number: 390 • 2016 ACR/ARHP Annual Meeting

    Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India

    Manjari Agarwal1, Abhay Shivpuri2, Sumidha Mittal3, Amit Khosla4 and Sujata Sawhney5, 1Institute of Child Health, Attending Consultant, New Delhi, India, 2Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, 3Post Doctoral Fellow, New Delhi, India, 4Department of Ophthalmology,Sir Ganga Ram Hospital, Senior Consultant, New Delhi, India, 5Paediatric rheumatology, Senior Consultant, New Delhi, India

    Background/Purpose:  Reference Adalimumab is not available in our country but biosimilar ZRC 3197 is(1). This is lower priced and as healthcare is primarily self funded…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences